Login
$BIOA
$5.21 -$0.01 (0.19%) After hours

$BIOA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027

02 Oct 2026 8-K: Other Events

BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e...

14 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026

01 Jul 2026 Form 4: Barton Shane, Principal Accounting Officer

Received 39,718 shares by exercise or conversion ($263K) · Sold 42,350 shares ($1.07M) · Received 20,216 shares by exercise or conversion ($132K) · 1 more

30 Jun 2026 144
29 Jun 2026 144
12 Jun 2026 Form 4: Hemrajani Rekha, Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Enright Patrick G, Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Pande Vijay Satyanand, Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Healy James, Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Davidson Michael H., Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Garnier Jean Pierre, Director

Granted 22,000 Stock Option (Right to Buy)

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2026, BioAge Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals:

15 May 2026 SCHEDULE 13G/A
15 May 2026 SCHEDULE 13G/A
08 May 2026 8-K: Results of Operations and Financial Condition

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support